Serveur d'exploration sur l'Indium - Analysis (France)

Index « Auteurs » - entrée « Jacques Barbet »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Jacques Augé < Jacques Barbet < Jacques Uziel  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 11.
Ident.Authors (with country if any)Title
000022 (2012) Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC).
000023 (2012) Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement.
000035 (2011) Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors.
000043 (2011) Antibody-Hapten Recognition at the Surface of Functionalized Liposomes Studied by SPR: Steric Hindrance of Pegylated Phospholipids in Stealth Liposomes Prepared for Targeted Radionuclide Delivery.
000063 (2009) Novel neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors.
000094 (2006) Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
000095 (2006) Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group.
000116 (2005) Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody.
000129 (2003) Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial.
000139 (2002) Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft.
000315 (????) Improved tumor selectivity of radiolabeled peptides by receptor and antigen dual targeting in the neurotensin receptor model.

List of associated KwdEn.i

Nombre de
documents
Descripteur
10Humans
7Animals
6Female
6Mice
5Radioimmunotherapy (methods)
4Mice, Nude
4Thyroid Neoplasms (radiotherapy)
3Adult
3Aged
3Cell Line, Tumor
3Iodine Radioisotopes (therapeutic use)
3Male
3Middle Aged
3Neoplasm Metastasis
3Radioimmunotherapy
3Receptors, Neurotensin (metabolism)
3Tissue Distribution
2Antibodies, Bispecific (adverse effects)
2Carcinoembryonic Antigen (immunology)
2Combined Modality Therapy
2Indium Radioisotopes (diagnostic use)
2Indium Radioisotopes (pharmacokinetics)
2Mice, Inbred BALB C
2Neoplasms (diagnosis)
2Neoplasms (metabolism)
2Neoplasms (radionuclide imaging)
2Pentetic Acid (pharmacokinetics)
2Prognosis
2Radioimmunotherapy (adverse effects)
2Survival Analysis
2Thyroid Neoplasms (diagnosis)
2Thyroid Neoplasms (pathology)
2Treatment Outcome
2Tumor Cells, Cultured
1Adenocarcinoma (diagnosis)
1Adenocarcinoma (metabolism)
1Aged, 80 and over
1Amino Acid Sequence
1Antibodies (blood)
1Antibodies (immunology)
1Antibodies (therapeutic use)
1Antibodies, Bispecific
1Antibodies, Bispecific (administration & dosage)
1Antibodies, Bispecific (chemistry)
1Antibodies, Bispecific (immunology)
1Antibodies, Bispecific (pharmacokinetics)
1Antibodies, Bispecific (therapeutic use)
1Antibodies, Monoclonal (administration & dosage)
1Antibodies, Monoclonal (adverse effects)
1Antibodies, Monoclonal (therapeutic use)
1Antibodies, Monoclonal, Humanized (adverse effects)
1Antibodies, Monoclonal, Humanized (therapeutic use)
1Antibody Specificity
1Antigens, Neoplasm (immunology)
1Avidin (administration & dosage)
1Bone Marrow (pathology)
1Breast Neoplasms (diagnosis)
1Breast Neoplasms (metabolism)
1Calcitonin (blood)
1Carcinoembryonic Antigen (blood)
1Carcinoembryonic Antigen (chemistry)
1Carcinoembryonic Antigen (metabolism)
1Carcinoembryonic Antigen (therapeutic use)
1Carcinoma (metabolism)
1Carcinoma (radiotherapy)
1Carcinoma, Medullary (pathology)
1Carcinoma, Medullary (therapy)
1Colonic Neoplasms (metabolism)
1Colonic Neoplasms (radiotherapy)
1Computer Simulation
1Disease Progression
1Dose Fractionation
1Doxorubicin (therapeutic use)
1Drug Combinations
1Drug Delivery Systems (methods)
1Gallium Radioisotopes (chemistry)
1Gallium Radioisotopes (diagnostic use)
1Haptens (administration & dosage)
1Haptens (adverse effects)
1Haptens (chemistry)
1Haptens (diagnostic use)
1Haptens (metabolism)
1Haptens (therapeutic use)
1Heterocyclic Compounds, 1-Ring (chemistry)
1Heterocyclic Compounds, 1-Ring (diagnostic use)
1Immunoglobulin G (therapeutic use)
1Indium (therapeutic use)
1Indium Radioisotopes (chemistry)
1Indium Radioisotopes (metabolism)
1Iodine Radioisotopes (administration & dosage)
1Iodine Radioisotopes (adverse effects)
1Iodine Radioisotopes (pharmacokinetics)
1Kinetics
1Ligands
1Metabolic Clearance Rate (drug effects)
1Neoplasm Transplantation
1Neoplasms (radiotherapy)
1Neoplasms (therapy)
1Neoplasms, Experimental
1Neurotensin (analogs & derivatives)

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=IndiumV2/Data/France/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i -k "Jacques Barbet" 
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i  \
                -Sk "Jacques Barbet" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=   *** parameter Area/wikiCode missing *** 
   |area=    IndiumV2
   |flux=    France
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    Jacques Barbet
}}

Wicri

This area was generated with Dilib version V0.5.76.
Data generation: Tue May 20 07:24:43 2014. Site generation: Thu Mar 7 11:12:53 2024